Dr Jules Derks. Photo credit: https://netrf.org/2025/05/28/unlocking-personalized-treatment-for-lung-neuroendocrine-tumors/
Innovative Research Fuels Hope for Personalised Lung Neuroendocrine Cancer Care
In a major advancement for patients with Lung Neuroendocrine Tumours (Lung NETs), a research team led by Dr Jules Derks at Maastricht University, in collaboration with the USA’s NET Research Foundation, has unveiled a significant step forward in the quest for personalised treatment for this rare and complex cancer type.
Published in a newly released report, the study presents a novel approach using a simple immunohistochemical (IHC) panel that accurately reflects the complex molecular makeup of Lung NETs. Dr Derks stated:
“Our work represents an important step toward personalized treatment for patients with Lung NETs. By showing that a simple immunohistochemical panel can reliably reflect complex molecular profiles in Lung NETs, we now have an accessible tool to stratify tumors into three biologically and clinically distinct subgroups.”
Why is this important?
This development is going to be critical going forward in terms of developing clinical trials for targeted therapies for this group of patients who still largely represent an unmet need for better treatment options.
Read the full published report below to explore the detailed findings:
https://netrf.org/2025/05/28/unlocking-personalized-treatment-for-lung-neuroendocrine-tumors/
To read about lung neuroendocrine cancer, you can visit our webpage HERE